Coronavirus Vaccine in Bottles

Pfizer-BioNTech Vaccine Proven To Reduce Symptomatic Covid-19 In Real World

Researchers in Israel this week announced that Pfizer-BioNTech’s Covid-19 vaccine has appeared to reduce symptomatic coronavirus infections by more than 90% in the real world now that more and more populations are receiving their doses. 

The preliminary findings suggest that the vaccine itself has remained as successful as researchers initially proved in their vaccine trials. Within a clinical vaccine trial the conditions are greatly controlled to monitor the actual effectiveness of the shot, however, that monitoring already eliminates a slew of other risks that exist within the real world that could impact the vaccine’s efficacy. 

Embed from Getty Images

Luckily, nothing of the sort has occurred, and the vaccine is still wildly successful. The Clalit Research Institute is a major part of Israel’s healthcare system, and they’re the ones who analyzed data on 1.2 million individuals; half of which received the Pfizer-BioNTech vaccine. The researchers wanted to compare patients who had received the vaccine and individuals with similar immune systems who hadn’t.

The researchers wanted to analyze the rate in which symptomatic Covid-19 was spreading with the release of this vaccine; meaning they looked at individuals who contracted the virus and actually felt sick. Symptomatic Covid-19 was proven to decrease by 94% among individuals who have received their two doses of the vaccine, according to a press release from Clalit. The rate of serious illness caused by the virus decreased by 92%. 

The research has yet to be published by the Institute because they’re still waiting for it to be peer-reviewed so that the results are as accurate as possible. However, the results are already consistent with the data that Pfizer initially released to prove their vaccine would be effective. 

Embed from Getty Images

Pfizer’s initial data from their vaccine trial showed that their Covid-19 vaccine was 95% effective against symptomatic coronavirus. In the trial itself, participants were either given the actual vaccine or a placebo. They then observed how many people from each group got infected after the fact. 

Pfizer’s clinical study was considered to be the “golden standard in clinical research” according to the Institute due to the fact that it was a randomized and controlled trial. The studies from Israel are now observational, meaning researchers aren’t randomly picking individuals who got the vaccine or not already.

Observational studies can skew the data in this case, however, due to the fact that different individuals who choose to be vaccinated are likely going to take less or more steps towards protecting themselves from potential infection. 

While the observational aspect of this study may not be as effective as a controlled trial, the combination of these new results with the results that came from Pfizer and BioNTech themselves shows the world that the vaccine is just as effective as anticipated, and we should all continue to do our parts to protect each other and bring this pandemic to an end.

Pfizer Says Final Analysis Shows Covid-19 Vaccine Is 95% Effective With No Safety Concerns

A final analysis of the Phase 3 trial of Pfizer’s Covid-19 vaccine shows that it’s 95% effective in preventing infections with no serious side effects, even in older adults. Of the participants that took part in the trial the company counted 170 cases of Covid-19; 162 of those infections were in people who were given the placebo vaccine, which was just plain saline, while eight of the infections were in those who got the actual vaccine, making the efficacy of Pfizer’s vaccine 95%.

Initially, Pfizer’s data showed that the vaccine was only 90% effective, which still would’ve been more than enough to be distributed and used among the world, however, after further analysis Pfizer and partner BioNTech claimed that “efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,” the two said in a joint statement. 

Embed from Getty Images

Pfizer claims that it will be seeking emergency use authorization from the US Food and Drug Administration “within days” now that they have these final results. The data will also be submitted to other regulatory agencies around the world for manufacturing and distribution. Dr. Ugur Sahin, CEO and co-founder of BioNTech, recently spoke with the media about how hopeful his whole team has been in regard to this vaccine and all the advancements the science community is starting to see that will help finally bring this pandemic to an end. 

“The rapid protection this vaccine provides — combined with its tolerability profile in all age groups studied so far — should help make this vaccine an important tool to address the current pandemic.”

The Phase 3 clinical trial for Pfizer’s vaccine began on July 27th. Of the 43,661 volunteers enrolled, 41,135 had received a second dose of either the vaccine or placebo. The FDA said that it wanted at least two months of safety tracking on said volunteers after they got their second dose. The companies also made it a point to hire as diverse of a group of volunteers as possible to ensure the vaccine won’t impact certain demographics differently. 

“Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age,” Pfizer said, adding that the 150 clinical trial sites in the United States, Germany, Turkey, South Africa, Brazil and Argentina will continue to collect information about efficacy and safety for two more years.

Embed from Getty Images

“Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.”

Pfizer has three US vaccine manufacturing sites located within Michigan and Massachusetts. Many states, however, have expressed their concern over the fragility of the Pfizer vaccine, which must be kept at a temperature of minus 75 degrees Celsius; far below the capacity of the average medical freezer located in pharmacies and doctors offices. 

However, Pfizer is confident that their custom vaccine packaging will maintain the vaccine’s freshness and ensure it remains safe and effective by the time it’s injected into patients. “The companies have developed specially designed, temperature-controlled thermal shippers utilizing dry ice to maintain temperature conditions of -70°C. They can be used as temporary storage units for 15 days by refilling with dry ice. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.”

Between this vaccine and Moderna’s announcement that their vaccine is also testing at 95% efficacy, the world is beginning to regain some hope in terms of this pandemic coming to an end. For now, however, it is imperative that every individual doesn their part to continue to curb the spread by wearing a mask, staying home, and social distancing when prompted.